Analysts remain cautious about Equillium, Inc. despite better earnings and revenue projections. The 35% reduction in price target signifies this. With anticipated 11% annual revenue decline by end of 2023, skepticism about Equillium's future performance compared to recent growth and industry peers is evident.
$Equillium(EQ.US)$This has turned into profit from losses; one indicator is important which is the operating profit which it managed to generate in positive... meaning the management managed to bring the operation expenses down and managing the cost well... However, people are ignoring this important figure and let's see whether the management can manage for subsequent quarters...still worth to take risks for this low price
Equillium股票討論區
Good move
Watch list
AH + 12/29 watchlist
$AMC Preferred Equity Unit(APE.US)$$Baudax Bio(BXRX.US)$$COMSovereign(COMS.US)$$Cosmos Health(COSM.US)$$Equillium(EQ.US)$$Hoth Therapeutics(HOTH.US)$$國際博彩科技(IGT.US)$$KALA BIO(KALA.US)$$美高梅(MGM.US)$$PDS Biotechnology(PDSB.US)$$Quotient(QTNT.US)$$TG Therapeutics(TGTX.US)$$特斯拉(TSLA.US)$$Minerva Surgical(UTRS.US)$
暫無評論